My prostate biopsy shows a Gleason score of 7, specifically 4+3. What does this mean, and what is the best treatment?
Quick Answer: What Does Gleason 4+3=7 Mean?
Gleason 4+3=7 prostate cancer is Grade Group 3. It is more clinically significant than Gleason 3+4=7 because pattern 4 is the dominant cancer pattern.
- Gleason 4+3=7 corresponds to ISUP Grade Group 3.
- If the cancer is still localized, Grade Group 3 is generally classified as unfavourable intermediate-risk prostate cancer.
- There is no single “best” treatment based on Gleason score alone. PSA, clinical stage, MRI, biopsy extent, imaging, age, general health and personal treatment priorities all matter.
- For a healthy man with localized disease and a life expectancy greater than about 10 years, common curative options include radical prostatectomy or radiation therapy combined with short-term androgen-deprivation therapy (ADT).
- Active surveillance is generally not recommended for Grade Group 3 disease.
- Radiation after prostatectomy is not automatic. Postoperative radiation is considered according to surgical pathology, PSA after surgery and evidence of persistent or recurrent disease.
What Does Gleason Score 4+3=7 Mean?
The Gleason system describes how prostate cancer looks under the microscope.
The pathologist identifies the two most important growth patterns in the biopsy and assigns them numerical grades.
In Gleason 4+3=7:
- 4 is the predominant pattern;
- 3 is the secondary pattern;
- and together they produce a Gleason score of 7.
Under the modern ISUP Grade Group system, Gleason 4+3=7 is Grade Group 3.
| Grade Group | Gleason Score | General Grade |
|---|---|---|
| 1 | 3+3=6 | Lowest grade routinely diagnosed as prostate cancer |
| 2 | 3+4=7 | Intermediate grade, mainly pattern 3 |
| 3 | 4+3=7 | Intermediate grade, mainly pattern 4 |
| 4 | Gleason 8 | Higher-grade cancer |
| 5 | Gleason 9–10 | Highest Grade Group |
Is Gleason 4+3 Worse Than Gleason 3+4?
Yes, the distinction is clinically important.
Both scores add up to seven, but they do not represent the same disease biology.
In Gleason 3+4, the lower-grade pattern 3 predominates.
In Gleason 4+3, the more abnormal pattern 4 predominates.
This is why:
- 3+4=7 is Grade Group 2;
- 4+3=7 is Grade Group 3;
- and Grade Group 3 generally carries a greater risk of recurrence and progression than Grade Group 2.
Do not interpret every Gleason score of seven as having the same prognosis.
Is Gleason 4+3=7 Intermediate-Risk Prostate Cancer?
If the cancer is clinically confined to the prostate or immediately localized region and other findings do not place it into a higher-risk category, Grade Group 3 generally falls into the unfavourable intermediate-risk group.
Current European guidelines classify ISUP Grade Group 3 with clinical T1–T2 disease as unfavourable intermediate risk.
But the Gleason score is only one part of risk classification.
For example:
- a PSA above 20 ng/mL can move a patient into a high-risk group;
- clinical T3–T4 disease indicates more advanced local disease;
- positive lymph nodes change staging and treatment;
- and distant metastases fundamentally change the treatment strategy.
Grade Is Not the Same as Stage
Gleason 4+3 tells us about the microscopic aggressiveness of the cancer. It does not by itself tell us whether the cancer is confined to the prostate, has reached lymph nodes or has spread elsewhere.
What Information Is Needed Before Choosing Treatment?
Before recommending surgery, radiation or another management strategy, the treating urologist and radiation oncologist need more information than the Gleason score alone.
Important information includes:
-
PSA level
PSA is an important component of prostate-cancer risk classification. -
Clinical stage
Whether the cancer is clinically T1, T2 or more locally advanced. -
MRI findings
MRI can help show the location and extent of disease within and around the prostate. -
Number of positive biopsy cores
The amount of cancer present across the biopsy matters. - Percentage of each core containing cancer
- Amount of Gleason pattern 4
- Cribriform or intraductal carcinoma, if reported, because these pathological features can carry additional prognostic significance.
- Prostate size and urinary function
- General health and estimated life expectancy
Would Additional Scans Be Needed for Grade Group 3?
Often, yes.
Current EAU guidance recommends additional staging for unfavourable intermediate-risk prostate cancer.
Where available, a PSMA PET/CT may be used to improve staging accuracy.
If PSMA PET/CT is not available, conventional staging may include cross-sectional abdominal/pelvic imaging and a bone scan.
Is Active Surveillance Appropriate for Gleason 4+3=7?
Generally, no.
Active surveillance is most firmly established for low-risk prostate cancer and can be considered for carefully selected men with favorable Grade Group 2 disease.
Current EAU guidance specifically recommends that Grade Group 3 cancers should be excluded from active-surveillance protocols.
That makes Gleason 4+3 different from carefully selected 3+4 cancers.
Active Surveillance Is Not the Same as Watchful Waiting
Active surveillance attempts to preserve a future opportunity for curative treatment while carefully monitoring the cancer.
Watchful waiting is generally used when age, significant medical illness or limited life expectancy means treatment would be given primarily if symptoms develop rather than with the intention of cure.
Radical Prostatectomy for Gleason 4+3 Prostate Cancer
Radical prostatectomy is one standard curative option for appropriately selected men with localized Grade Group 3 prostate cancer.
During radical prostatectomy, the entire prostate gland and seminal vesicles are removed.
Depending on estimated lymph-node risk, lymph-node assessment or dissection may also be considered.
Advantages can include:
- removal of the primary tumor;
- detailed pathological examination of the entire prostate after surgery;
- precise pathological staging;
- and PSA should usually fall to an undetectable or very low level after successful prostate removal.
Important potential adverse effects include:
- urinary incontinence;
- erectile dysfunction;
- surgical and anesthetic risks;
- loss of ejaculation and infertility;
- and possible later treatment if cancer persists or returns.
Radiation Therapy for Gleason 4+3 Prostate Cancer
Radiation therapy is another major curative option for localized unfavourable intermediate-risk prostate cancer.
Modern external-beam treatment typically uses techniques such as IMRT/VMAT with image guidance.
For unfavourable intermediate-risk disease, current guidelines generally recommend combining radiation with short-term androgen-deprivation therapy (ADT), commonly about four to six months.
Selected men with good urinary function may also be candidates for a brachytherapy boost combined with external-beam radiation and short-term ADT.
Possible Radiation Side Effects
These can include:
- temporary urinary frequency or urgency;
- bowel irritation;
- fatigue;
- erectile dysfunction that may develop over time;
- and less commonly longer-term urinary or bowel problems.
Possible ADT Side Effects
Short-term hormonal treatment may cause:
- hot flushes;
- fatigue;
- reduced libido;
- erectile difficulties;
- mood changes in some patients;
- and metabolic or body-composition changes.
Does Radical Prostatectomy Have to Be Followed by Radiotherapy?
No.
This is an important correction to the older answer on this page.
Radiation is not routinely given to every man after radical prostatectomy.
After surgery, decisions depend on:
- the final pathological Grade Group;
- whether cancer extends outside the prostate;
- seminal-vesicle involvement;
- surgical-margin status;
- lymph-node findings;
- postoperative PSA;
- and whether PSA remains detectable or later begins to rise.
Modern evidence has increasingly supported PSA surveillance with early salvage radiotherapy when appropriate rather than automatically irradiating every patient immediately after surgery.
Surgery First Does Not Automatically Mean Surgery + Radiation
Some men are cured by surgery alone. Others need salvage radiation because postoperative PSA remains detectable or rises later. A smaller group with particularly adverse pathological findings may be considered for additional postoperative treatment.
Surgery vs Radiation + ADT for Gleason 4+3
There is no universal answer showing that one approach is best for every man with Grade Group 3 prostate cancer.
| Consideration | Radical Prostatectomy | Radiation + Short-Term ADT |
|---|---|---|
| Goal | Curative local treatment | Curative local treatment |
| Prostate | Removed surgically | Remains in place and is treated with radiation |
| Pathology afterward | Entire prostate can be examined | No surgical specimen |
| Hormone treatment | Not routinely required with initial surgery | Usually short-term ADT for unfavourable intermediate risk |
| Urinary incontinence | Important potential surgical adverse effect | Usually less immediate incontinence risk, but urinary irritation can occur |
| Erectile function | May decline soon after surgery | May decline gradually; ADT temporarily affects sexual function |
| Bowel effects | Usually not a major long-term effect | Radiation can cause bowel irritation in some patients |
| Further treatment | Salvage radiation remains possible if recurrence occurs | Local salvage after radiation is possible but can be more complex |
The decision should therefore be based on cancer control and which side-effect profile matters most to the individual patient.
How Do Age and Life Expectancy Affect the Decision?
Another correction is necessary here.
A diagnosis of Gleason 4+3 prostate cancer does not mean that life expectancy is “10 years.”
The approximately 10-year figure used in guidelines refers instead to estimated life expectancy before treatment decisions.
If a man is otherwise healthy and expected to live more than about 10 years, the long-term benefit of curative treatment becomes more relevant.
If severe medical problems or advanced age substantially limit life expectancy, the balance can change because treatment side effects may outweigh the likely long-term cancer benefit.
Therefore, doctors consider:
- age;
- heart and lung health;
- diabetes and other chronic illnesses;
- frailty;
- functional independence;
- and overall life expectancy rather than age alone.
So Which Treatment Is “Best” for Gleason 4+3?
For a man with localized Grade Group 3 prostate cancer who is healthy enough for curative treatment, the main discussion is commonly between:
I would not choose between surgery and radiation simply from the phrase “Gleason 4+3.”
Questions to Ask the Urologist and Radiation Oncologist
Before choosing treatment, I would suggest asking:
- What is my exact PSA?
- What is my clinical stage?
- Is the cancer still confined to the prostate?
- What did the MRI show?
- Do I need a PSMA PET/CT or other staging scans?
- How many biopsy cores contain Grade Group 3 cancer?
- Is cribriform or intraductal cancer present?
- What is my estimated chance of cure with surgery?
- What radiation approach would you recommend, and how long would ADT be used?
- How would each treatment affect my urinary control, erections, bowel function and quality of life?
- If I choose surgery, under what circumstances would I later need radiation?
Consider Hearing Both Specialists
For localized Grade Group 3 prostate cancer, it is often useful to hear both a urologic surgeon’s and a radiation oncologist’s assessment before choosing between potentially curative treatments.
Dr. Albana’s Answer
Hello Mel,
A Gleason score of 4+3=7 means Grade Group 3 prostate cancer.
The fact that the 4 comes first is important because pattern 4 is the predominant component. Therefore, 4+3 disease is considered more concerning than 3+4 disease even though both scores total seven.
I cannot tell you which treatment is best from the Gleason score alone. I would first want to know your PSA, clinical stage, MRI findings, number of positive biopsy cores, amount of cancer in those cores and whether staging shows disease outside the prostate.
If this is localized Grade Group 3 disease and you are otherwise healthy with a life expectancy greater than about 10 years, current guidelines generally support definitive treatment. The main options are commonly radical prostatectomy or radiation therapy combined with short-term androgen-deprivation therapy.
I would not routinely recommend active surveillance for Gleason 4+3. Current European guidance specifically excludes Grade Group 3 disease from active-surveillance protocols.
I also want to correct something from the older version of my answer: radical prostatectomy does not automatically need to be followed by radiotherapy. Some men are cured by surgery alone. Postoperative radiation is considered according to the final pathology and, importantly, what the PSA does after surgery.
If you have your complete pathology report, PSA and imaging results, those are the pieces of information your treating urologist and radiation oncologist will use to place you into the correct risk group and discuss the advantages and disadvantages of each treatment.
— Dr. Albana Greca, MD, MMedSc, Family Physician / General Practitioner
Most Asked Questions About Gleason 4+3=7
Is Gleason 4+3=7 serious?
It is clinically significant prostate cancer. Gleason 4+3 corresponds to Grade Group 3 and has greater progression risk than Gleason 3+4. However, localized Grade Group 3 prostate cancer can still often be treated with curative intent.
Is Gleason 4+3 worse than 3+4?
Yes. In 4+3, the more aggressive Gleason pattern 4 makes up the predominant component. This is Grade Group 3, whereas 3+4 is Grade Group 2.
Is Gleason 4+3 high-risk prostate cancer?
Grade Group 3 with clinical T1–T2 disease is generally classified as unfavourable intermediate risk. However, PSA above 20, more advanced clinical stage, lymph-node involvement or metastatic disease can place a patient into a higher-risk category.
Can Gleason 4+3 prostate cancer be cured?
Localized Grade Group 3 cancer is commonly treated with curative intent. The individual chance of cure depends on PSA, stage, biopsy burden, imaging, pathological features and the treatment selected.
Can Gleason 4+3 be managed with active surveillance?
Current EAU guidance recommends excluding Grade Group 3 disease from active-surveillance protocols. This differs from selected low-volume Grade Group 2 cancers, for which surveillance may sometimes be considered.
Is surgery better than radiation for Gleason 4+3?
There is no universally superior treatment for every patient. Radical prostatectomy and radiation combined with appropriate ADT are both established curative approaches for appropriately selected men. Age, health, anatomy, urinary function, sexual priorities and cancer extent help determine which approach fits best.
How long is hormone therapy used with radiation for Gleason 4+3?
For unfavourable intermediate-risk prostate cancer, current guidelines commonly recommend short-term ADT for approximately four to six months when radiation therapy is used.
Will I automatically need radiation after prostate surgery?
No. Many men need no immediate radiation after prostatectomy. Postoperative treatment depends on the surgical pathology and PSA. Early salvage radiation may be recommended if PSA persists or later begins to rise.
Do I need a PSMA PET scan with Gleason 4+3?
Current EAU guidance recommends PSMA PET/CT, when available, to improve staging accuracy for unfavourable intermediate-risk prostate cancer. Whether it is appropriate in your case should be decided by your treating cancer team.
Related Prostate Cancer & Testing Guides
Medical References
-
European Association of Urology.
EAU Guidelines on Prostate Cancer — Classification and Staging.
2026.
EAU Classification & Staging -
European Association of Urology.
EAU Guidelines on Prostate Cancer — Treatment.
2026.
EAU Prostate Cancer Treatment Guideline -
European Association of Urology.
EAU Guidelines on Prostate Cancer — Diagnostic Evaluation and
Staging.
2026.
EAU Diagnostic Evaluation -
American Urological Association / American Society for Radiation
Oncology.
Clinically Localized Prostate Cancer Guideline.
AUA/ASTRO Guideline -
American Urological Association / ASTRO / SUO.
Salvage Therapy for Prostate Cancer Guideline.
2024.
AUA/ASTRO/SUO Salvage Guideline -
National Cancer Institute.
Prostate Cancer Treatment (PDQ®).
National Cancer Institute
Medical information notice: Gleason score alone is not sufficient to select an individual prostate cancer treatment. PSA, clinical stage, biopsy findings, MRI/staging, overall health, life expectancy and patient preferences must all be considered. Treatment decisions should be made with the treating urologist and, when radiation is an option, a radiation oncologist.
Written & medically reviewed by Dr. Albana Greca, MD, MMedSc • Family Physician / General Practitioner • Last medically reviewed: August 2026